SLDB vs. OCGN, TRML, BDTX, TCRX, AURA, REPL, TNYA, ALVO, FATE, and LXEO
Should you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Ocugen (OCGN), Tourmaline Bio (TRML), Black Diamond Therapeutics (BDTX), TScan Therapeutics (TCRX), Aura Biosciences (AURA), Replimune Group (REPL), Tenaya Therapeutics (TNYA), Alvotech (ALVO), Fate Therapeutics (FATE), and Lexeo Therapeutics (LXEO). These companies are all part of the "biological products, except diagnostic" industry.
Ocugen (NASDAQ:OCGN) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
Ocugen has higher earnings, but lower revenue than Solid Biosciences. Ocugen is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Ocugen's return on equity of -62.11% beat Solid Biosciences' return on equity.
In the previous week, Ocugen had 8 more articles in the media than Solid Biosciences. MarketBeat recorded 9 mentions for Ocugen and 1 mentions for Solid Biosciences. Ocugen's average media sentiment score of 1.88 beat Solid Biosciences' score of 0.32 indicating that Solid Biosciences is being referred to more favorably in the news media.
Solid Biosciences received 151 more outperform votes than Ocugen when rated by MarketBeat users. However, 68.49% of users gave Ocugen an outperform vote while only 67.47% of users gave Solid Biosciences an outperform vote.
10.3% of Ocugen shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 3.5% of Ocugen shares are owned by company insiders. Comparatively, 19.3% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Ocugen has a beta of 3.49, suggesting that its stock price is 249% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500.
Ocugen presently has a consensus target price of $4.67, suggesting a potential upside of 165.91%. Solid Biosciences has a consensus target price of $18.25, suggesting a potential upside of 84.72%. Given Solid Biosciences' higher possible upside, research analysts clearly believe Ocugen is more favorable than Solid Biosciences.
Summary
Solid Biosciences beats Ocugen on 9 of the 16 factors compared between the two stocks.
Get Solid Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Solid Biosciences Competitors List
Related Companies and Tools
